<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35321">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133820</url>
  </required_header>
  <id_info>
    <org_study_id>HMX1507</org_study_id>
    <secondary_id>2013-005522-35</secondary_id>
    <nct_id>NCT02133820</nct_id>
  </id_info>
  <brief_title>A Study to Assess How the Body Processes a Strong Painkiller When it is Given Alongside a Drug That Counteracts the Side Effects of Strong Painkillers in a Fasted and Fed State.</brief_title>
  <official_title>A 4-part, Single-dose, Open-label, Randomised, Crossover, Exploratory Study in Healthy Subjects to Assess the Influence of an Opioid Antagonist on How the Body Processes a Strong Painkiller, When Co-administered in a Fasted and Fed State.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Research Limited</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether an opioid antagonist has any impact on the release of a strong painkiller
      in the blood when it is given to healthy volunteers when they have eaten and also when they
      have fasted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an exploratory study to assess the influence of an opioid antagonist on the
      pharmacokinetics of a strong painkiller when co-administered in a fasted and fed state.

      Determination is by measurement of drug concentrations in the blood at serial collection
      time points pre-dose until 32 hours post-dose, following an administration of a single oral
      dose. Pharmacokinetics parameters of AUC and Cmax are the primary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics parameters AUC and Cmax</measure>
    <time_frame>Up to 32 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>7 to 10 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>AEs will be recorded through spontaneous reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>0 to  32 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vital signs - blood pressure, pulse rate, tympanic temperature and respiration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Day 0 and Day 7-10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical laboratory tests - blood samples will be taken at screening and post-study medical for routine laboratory analysis (haematology, blood chemistry and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>Screening, 1 our post-dose and Day 7-10</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ECGs</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>12 hourly capsule fasted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg 12 hourly capsule - strong pain killer fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 hourly capsule fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg 12 hourly capsule - strong pain killer fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 hourly capsule with antagonist fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg 12 hourly capsule strong painkiller with antagonist fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 hourly capsule with antagonist fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg 12 hourly capsule strong painkiller with antagonist fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg 12 hourly capsule - strong pain killer fasted</intervention_name>
    <arm_group_label>12 hourly capsule fed</arm_group_label>
    <other_name>MR2XXX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg 12 hourly capsule - strong pain killer fed</intervention_name>
    <arm_group_label>12 hourly capsule fasted</arm_group_label>
    <other_name>MR2XXX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12 hourly capsule strong painkiller with antagonist fasted)</intervention_name>
    <arm_group_label>12 hourly capsule with antagonist fed</arm_group_label>
    <other_name>MR2XXX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg 12 hourly capsule strong painkiller with antagonist fed</intervention_name>
    <arm_group_label>12 hourly capsule with antagonist fasted</arm_group_label>
    <other_name>MR2XXX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy male or female subjects aged 18 to 55 inclusive Healthy and free of significant
        abnormal findings as determined by medical history, physical examination, vital signs,
        laboratory tests and ECG.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margaret C Wilson</last_name>
    <email>info@contact-clinical-trial.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jill Kiteley</last_name>
    <email>info@contact-clinical-trial.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Quotient Clinical Limited</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Collier</last_name>
    </contact>
    <investigator>
      <last_name>Dr Collier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Narcotic Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
